Atypical Endometrial Hyperplasia in a Woman Who Wants to Conceive
39-year-old nulligravida with PCOS, BMI 41 kg/m², HbA1c 7.8%, and 8 months of oligomenorrhea followed by heavy bleeding. Transvaginal ultrasound shows endometrial thickness 16 mm; office Pipelle biopsy shows atypical endometrial hyperplasia. She has no family history of Lynch syndrome, and immunohistochemistry shows retained mismatch repair proteins. She has hypertension controlled with amlodipine and takes metformin 1,000 mg twice daily. Her fasting insulin is elevated, and she has acanthosis nigricans. She has never used hormonal contraception. Her mother had type 2 diabetes. She is desperate to conceive and asks whether she can start IVF next month and defer hysterectomy until after a baby. She has no adnexal mass, and renal and liver function are normal. The clinic has a reproductive endocrinologist and a gynecologic oncologist.
1. What is the risk that she already has endometrial cancer, and why is immediate IVF inappropriate?
Read the worked answer
Atypical endometrial hyperplasia carries a substantial risk of concurrent endometrial cancer, commonly cited as roughly 30–40%, and some of these cancers have myometrial invasion. Immediate IVF would expose her to controlled ovarian stimulation with high estrogen levels, which is mitogenic to endometrial tissue and could allow progression during the time needed for pregnancy. Pregnancy should be deferred until regression is documented by repeat endometrial sampling. Her BMI of 41 kg/m², HbA1c of 7.8%, and chronic anovulation are independent risk factors for both persistence and progression. She needs gynecologic oncology input, counseling about definitive surgery, and a documented discussion that fertility-sparing treatment is not standard curative therapy.
2. Design a fertility-sparing plan with specific agents, surveillance intervals, and stopping rules.
Read the worked answer
Reasonable options include oral megestrol acetate 160–320 mg/day or a 52-mg levonorgestrel intrauterine system, recognizing that the intrauterine system is not specifically approved for this indication. Add metformin 1,000 mg twice daily, target weight loss, and improve glycemic control. Repeat endometrial sampling at 3 months; if regression is present, continue treatment and sample every 3–6 months. If there is no regression by 6–9 months or if progression occurs, recommend hysterectomy. Once regression is documented, refer to reproductive endocrinology and proceed with ovulation induction or IVF only while maintaining progestin therapy or the intrauterine system. Contraception is mandatory during treatment. Counsel that recurrence after regression is common and that hysterectomy is recommended after childbearing.
3. What definitive management and counseling should be provided after she completes childbearing?
Read the worked answer
Hysterectomy is the definitive treatment because it eliminates the risk of progression and recurrence. Bilateral salpingectomy can be performed for ovarian cancer risk reduction; ovaries may be preserved if they appear normal in a premenopausal woman, but this should be individualized given her obesity and diabetes. If cancer is found at hysterectomy, staging is performed according to depth of invasion and grade. She should be counseled that fertility-sparing treatment does not remove the risk of endometrial cancer and that abnormal bleeding after treatment requires immediate evaluation. Weight management and glycemic control remain important because they reduce recurrence risk and perioperative complications. Lynch syndrome was not suggested by immunohistochemistry, but a detailed family history should still be obtained.